AMAM has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AMAM has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Ambrx Biopharma's Total Liabilities for the quarter that ended in Jun. 2023 was $29.56 Mil. Ambrx Biopharma's Total Assets for the quarter that ended in Jun. 2023 was $279.94 Mil. Therefore, Ambrx Biopharma's Liabilities-to-Assets Ratio for the quarter that ended in Jun. 2023 was 0.11.
The historical data trend for Ambrx Biopharma's Liabilities-to-Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ambrx Biopharma Annual Data | |||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | |||||
Liabilities-to-Assets | 0.42 | 2.03 | 0.17 | 0.20 |
Ambrx Biopharma Quarterly Data | ||||||||
Dec19 | Jun20 | Dec20 | Jun21 | Dec21 | Jun22 | Dec22 | Jun23 | |
Liabilities-to-Assets | Get a 7-Day Free Trial | 0.10 | 0.17 | 0.22 | 0.20 | 0.11 |
For the Biotechnology subindustry, Ambrx Biopharma's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Ambrx Biopharma's Liabilities-to-Assets distribution charts can be found below:
* The bar in red indicates where Ambrx Biopharma's Liabilities-to-Assets falls into.
Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.
Ambrx Biopharma's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2022 is calculated as:
Liabilities-to-Assets (A: Dec. 2022 ) | = | Total Liabilities | / | Total Assets |
= | 29.127 | / | 146.977 | |
= | 0.20 |
Ambrx Biopharma's Liabilities-to-Assets Ratio for the quarter that ended in Jun. 2023 is calculated as
Liabilities-to-Assets (Q: Jun. 2023 ) | = | Total Liabilities | / | Total Assets |
= | 29.564 | / | 279.944 | |
= | 0.11 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ambrx Biopharma (NAS:AMAM) Liabilities-to-Assets Explanation
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.
Thank you for viewing the detailed overview of Ambrx Biopharma's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Cormorant Asset Management, Lp | 10 percent owner | 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116 |
Margaret Dalesandro | director | ONCOSEC MEDICAL INCORPORATED, 24 NORTH MAIN STREET, PENNINGTON NJ 08534 |
Sonja Nelson | officer: Chief Financial Officer | C/O MOTUS GI HOLDINGS, INC., 1301 EAST BROWARD BOULEVARD, 3RD FLOOR, FT. LAUDERDALE FL 33301 |
Daniel J. O'connor | director, officer: President and CEO | C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022 |
Abhishek Trehan | 10 percent owner | WHITELEY CHAMBERS, DON STREET, ST. HELIER Y9 JE2 4TR |
Darwin Global Master Fund, Ltd. | 10 percent owner | C/O OGIER GLOBAL (CAYMAN) LIMITED, 89 NEXUS WAY, CAMANA BAY, GRAND CAYMAN E9 KY1-9009 |
Paul V Maier | director | 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121 |
Janet Loesberg | director | C/O AMBRX BIOPHARMA INC., 10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037 |
Kate Hermans | director | C/O AMBRX BIOPHARMA INC., 10975 TORREY PINES ROAD, LA JOLLA CA 92037 |
Xiaowei Chang | director | 10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037 |
Stephen C. Glover | director | 108 DOCKSIDE CIRCLE, WESTON FL 33327 |
Andrew Aromando | officer: Chief Operating Officer | C/O AMBRX BIOPHARMA INC., 10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037 |
Cormorant Private Healthcare Fund Iii Lp | 10 percent owner | 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116 |
Cormorant Global Healthcare Master Fund, Lp | 10 percent owner | 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116 |
Bihua Chen | 10 percent owner | C/O CORMORANT ASSET MANAGEMENT, LP, 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116 |
From GuruFocus
By sperokesalga sperokesalga • 05-04-2023
By sperokesalga sperokesalga • 05-24-2023
By Marketwired • 08-01-2023
By sperokesalga sperokesalga • 05-11-2023
By PRNewswire • 01-16-2024
By Business Wire Business Wire • 02-03-2023
By Business Wire • 01-08-2024
By Business Wire • 01-10-2024
By Business Wire Business Wire • 02-16-2023
By Marketwired • 06-28-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.